Cases & Deals

BioMarin acquires LEAD Therapeutics

Clients BioMarin Pharmaceutical, Inc.

Jones Day advised BioMarin Pharmaceutical, Inc. in connection with the acquisition of LEAD Therapeutics, Inc., a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers. BioMarin will pay to the stockholders of LEAD $18 million upfront and will pay an additional $11 million upon acceptance of the investigational new drug filing (filing expected by the end of 2010), and up to $68 million for development and launch milestones for LT-673.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.